NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
Clinical Trials
11 trialsNCT07076680 2025-11-28
A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
SciClone Pharmaceuticals
Withdrawn
NCT04659603 2025-10-01
CARMEN-BT01
Sanofi
Phase 2 Terminated
NCT04509596 2025-04-01
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
Phase 1 Completed
NCT05420779 2024-05-08
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
Tasly Pharmaceutical Group Co., Ltd
Phase 2 Recruiting
NCT04262804 2023-08-22
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
Phase 2 Unknown
NCT05301010 2023-02-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT05301530 2022-03-29
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 1 Completed
NCT04556292 2020-09-21
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 2 Unknown
NCT01876251 2019-03-15
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Pfizer
Phase 1 Terminated
NCT02664103 2018-02-01
METRO-ABC
Sanofi
Phase 2 Completed